Show simple item record

dc.contributor.authorRivera Izquierdo, Mario 
dc.contributor.authorMorales-Portillo, Arturo
dc.contributor.authorGuerrero Fernández de Alba, Inmaculada
dc.contributor.authorFernández Martínez, Nicolás Francisco
dc.contributor.authorSchoenenberger-Arnaiz, Joan Antoni
dc.contributor.authorBarranco-Quintana, José Luis
dc.contributor.authorValero-Ubierna
dc.contributor.authorValero Ubierna, María del Carmen
dc.date.accessioned2024-10-04T10:55:11Z
dc.date.available2024-10-04T10:55:11Z
dc.date.issued2024-09-23
dc.identifier.citationRivera-Izquierdo, M., Morales-Portillo, A., Guerrero-Fernández de Alba, I., Fernández-Martínez, N. F., Schoenenberger-Arnaiz, J. A., Barranco-Quintana, J. L., & Valero-Ubierna, C. (2024). Vaccination strategies for patients under monoclonal antibody and other biological treatments: an updated comprehensive review based on EMA authorisations to January 2024. Expert Review of Vaccines, 23(1), 887–910. https://doi.org/10.1080/14760584.2024.2401839es_ES
dc.identifier.urihttps://hdl.handle.net/10481/95540
dc.description.abstractIntroduction: Monoclonal antibodies (mAbs) and other biological agents are being increasingly approved in the last years with very different indications. Their highly heterogeneous immunosuppressive effects, mechanisms of action and pharmacokinetics require comprehensive individualized vaccination schedules. Areas covered: Vaccination for immunocompromised patients. Prevention and treatment with mAbs and other biological therapies. Expert opinion: Current recommendations on vaccine schedules for patients under mAbs or other biological treatments are based on expert opinions and are not individualized according to each vaccine and treatment. No studies are focusing on the high heterogeneity of these agents, which are exponentially developed and used for many different indications. Recent paradigm changes in vaccine development (boosted by the COVID-19 pandemic) and in the mAbs use for prophylactic purposes (changing ‘vaccination’ by ‘immunization’ schedules) has been witnessed in the last years. We aimed at collecting all mAbs used for treatment or prevention, approved as of 1 January 2024, by the EMA. Based on available data on mAbs and vaccines, we propose a comprehensive guide for personalizing vaccination. Recent vaccine developments and current population strategies (e.g. zoster vaccination or prophylactic nirsevimab) are discussed. This review aims to be a practical guideline for professionals working in vaccine consultations for immunosuppressed patients.es_ES
dc.description.sponsorshipInstituto de Investigación Biomédica de Lleida, Fundación Dr Pifarré (IRBLleida)es_ES
dc.language.isoenges_ES
dc.rightsAtribución-NoComercial 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subjectBiologic therapyes_ES
dc.subjectBiologics es_ES
dc.subjectImmunosuppressiones_ES
dc.titleVaccination strategies for patients under monoclonal antibody and other biological treatments: an updated comprehensive review based on EMA authorisations to January 2024es_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.1080/14760584.2024.2401839
dc.type.hasVersionVoRes_ES


Files in this item

[PDF]

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial 4.0 Internacional
Except where otherwise noted, this item's license is described as Atribución-NoComercial 4.0 Internacional